The Validity and Reliability of the Turkish Version of the Combined Index of Severity of Fibromyalgia

Sponsor
European University of Lefke (Other)
Overall Status
Recruiting
CT.gov ID
NCT03800199
Collaborator
(none)
200
1
1
62.6
3.2

Study Details

Study Description

Brief Summary

The aim of the investigator's study is to determine the validity and reliability of the Turkish version of the Combined Index of Severity (ICAF) in Turkish patients with Fibromyalgia Syndrome (FMS).

Condition or Disease Intervention/Treatment Phase
  • Other: Perceptive rehabilitation
N/A

Detailed Description

The original form of the Combined Index of Severity of Fibromyalgia (ICAF) will be translated into Turkish by two Turkish mother tongue translators who also speak English in advanced level. Then these translations will be combined into one translation and translated back to English. These translations will send to 7 different health professions who had experience working with FMS patients. The pre-final version will be composed and tested on a group of patients with FMS. If necessary, readjustments will be made, and the final version will be investigated in FMS patients. Acceptability was assessed in terms of refusal rate, rates of missing responses, and administration time. Reliability was assessed using Cronbach's alpha and test-retest assessments. Re-test assessments will be conducted after one week from first assessment. Content validity was assessed by examining the floor and ceiling effects and skew of the distributions. Convergent and divergent validity was assessed by examining the Pearson's correlation coefficients. In addition, the confirmatory factor analysis will be done to evaluate the validity of ICAF. Responsiveness was determined by examining effect size (ES), standardized response means (SRM) and P values generated using Wilcoxon's test.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Questionnaire: Combined Index of Severity of Fibromyalgia (ICAF) Intervention: Perceptive rehabilitation Procedure: Assessment of reliability, acceptability, validity and responsiveness.Questionnaire: Combined Index of Severity of Fibromyalgia (ICAF) Intervention: Perceptive rehabilitation Procedure: Assessment of reliability, acceptability, validity and responsiveness.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
The Validity and Reliability of the Turkish Version of the Combined Index of Severity of Fibromyalgia
Actual Study Start Date :
Apr 13, 2019
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Perceptive Rehabilitation (PR-group)

Perceptive rehabilitation group will receive a treatment that, as described by on Paolucci et al. (2015). This treatment will include small latex cones with different resistance. In each session there will be over 100 cones will be placed on a rigid wood with using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks. There will be in total 16 sessions.

Other: Perceptive rehabilitation
The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.

Outcome Measures

Primary Outcome Measures

  1. Combined Index of Severity of Fibromyalgia [Changes from baseline severity at 12 weeks.]

    Composed of 59 items, measures the combined severity index of fibromyalgia divided into 4 factors: physical, emotional, social and active and passive coping.The ICAF score ranges from 0 to 84, with higher values indicating higher severity.

Other Outcome Measures

  1. Revised-Fibromyalgia Impact Questionnaire (FIQR) [Changes from baseline at 12 weeks.]

    The Turkish version of FIQR will be used in this study. This questionnaire has 21 individual questions. All these questions should be answered according to the past 7 days. FIQR has divided into three sections; 'function, overall impact and symptoms'. The total FIQR score will be calculated with the sum of the three domain scores. The total score will be out of 100. The higher score means a severe impact.

  2. Socio-demographic and clinical characteristics [Changes from baseline at 12 weeks.]

    Date of birth, sex, marital status, profession, education status and time of the diagnosis of FMS will be noted.

  3. Body Mass Index (BMI) [Changes from baseline at 12 weeks.]

    Weight and height will be combined to report BMI in kg/m^2.

  4. Stanford Health Assessment Questionnaire (HAQ) [Changes from baseline at 12 weeks.]

    This questionnaire will be use to asses general health of the participants.There are 20 questions in 8 sub categories of functioning (dressing, rising, eating, walking, hygiene, reach, grip, and usual activities), 1 question is about pain and 1 question is about general health. Disability index questions has four possible answers (without any difficulty: 0, with some difficulty: 1, with much difficulty: 2, unable to do: 3). Highest score represent the worsening.

  5. Fatigue Severity Scale (FSS) [Changes from baseline at 12 weeks.]

    Turkish version of Fatigue Severity Scale (FSS) will be used in this study. This scale has 9 items. Each item should be scored (strongly disagrees) 0 to 7 (strongly agrees). The minimum score=9 and maximum score possible=63. Higher score=greater fatigue severity. The average score for all 9 items constitutes the FSS score.

  6. Short-Form 36 (SF-36) [Changes from baseline at 12 weeks.]

    The quality of life questionnaire Short Form 36 (SF-36) is multidimensional, consisting of 36 items, divided into eight scales, each scale assesses a health concept, they are: limitations in physical activities because of health problems, limitations in social activities due to physical or emotional problems, limitations in daily activities due to health problems, body pain, mental health, limitations in daily activities due to emotional problems, vitality, perception of general health. All categories have their own score out of 100. Higher scores mean a better quality of life.

  7. Pittsburgh Sleep Quality Index (PSQI) [Changes from baseline at 12 weeks.]

    Turkish version of Pittsburgh Sleep Quality Index (PSQI) will be used in this study. This is a self-reported index that has 19 items with Likert and open-ended response formats. This index should be answered according to the past month. Minimum Score "0" means "good sleep" and Maximum Score "30" means "disrupted sleep".

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Having a Fibromyalgia diagnosis according to Wolfe et al. (2016) criteria.

  • Feeling Fibromyalgia symptoms last 3 mounts

Exclusion Criteria:
  • Having physical and functional problems with FMS

  • Having a diagnosis of chronic pain other than FMS,

  • Using medicine other than simple analgesics,

  • History of cardiovascular or pulmonary diseases

  • Can not read and write in Turkish language

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eastern Mediterranean University Famagusta Cyprus

Sponsors and Collaborators

  • European University of Lefke

Investigators

  • Principal Investigator: Beraat Alptug, MSc, European University of Lefke
  • Principal Investigator: Emine H. Tüzün, Prof. Dr., Eastern Mediterranean University
  • Principal Investigator: Levent Eker, M. D., Eastern Mediterranean University
  • Principal Investigator: Gülbin Ergin, PhD, European University of Lefke

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Beraat Alptug, Master Physiotherapist/ Principal Investigator, European University of Lefke
ClinicalTrials.gov Identifier:
NCT03800199
Other Study ID Numbers:
  • ETK00-2018-0281
First Posted:
Jan 11, 2019
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Beraat Alptug, Master Physiotherapist/ Principal Investigator, European University of Lefke
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022